Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 23, Issue 1, 1998, Pages 19-26

  Katashima, Masataka ^a   Yamamoto, K ^b   Tokuma, Y ^a   Hata, T ^a   Sawada, Y ^c   Iga, T ^b  

^a ASTELLAS PHARMA INC   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

Lansoprazole; Omeprazole; Pantoprazole; Pharmacodynamics; Pharmacokinetics

Indexed keywords

HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

AREA UNDER THE CURVE; ARTICLE; DISSOCIATION CONSTANT; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; ENZYME INHIBITOR COMPLEX; HUMAN; MODEL; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; STOMACH ACID SECRETION;

EID: 0031972195     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03189822     Document Type: Article

References (33)

1. Colin W.H. (1991) : Clinical pharmacology of omeprazole. Clin. Pharmacokinet., 20, 38-49.
2. McTavish D., Buckley M.M.T., Heel R.C. (1991) : Omeprazole. Drugs. 42, 138-170.
3. Barradell L.B., Faulds D., McTavish D. (1992) : Lansoprazole. Drugs, 44, 225-250.
4. Spencer C.M., Faulds D. (1994) : Lansoprazole, a reappraisal of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs, 48, 404-430.
5. Means J.M., Kaplan B. (1996) : Proton pump inhibitors: new drugs and indications. Am. Fam. Physician, 53, 285-292.
6. Wolfe M.M., Soll A.H. (1988) : The physiology of gastric acid secretion. N. Engl. J. Med., 319, 1707-1715.
7. +-ATPase. Annu. Rev. Physiol., 52, 321-344.
8. +)-adenosine triphosphatase by the proton pump inhibitor AG-1749. J. Pharmacol. Exp. Ther., 248, 799-805.
9. Nagaya H., Satoh H., Maki Y. (1990) : Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in the isolated canine parietal cells. J. Pharmacol. Exp. Ther., 252, 1289-1295.
10. +-ATPase: the site of action of omeprazole. Scand. J. Gastroenterol., 24 (Suppl 166), 3-11.
11. Wallmark B. (1989) : Omeprazole: mode of action and effect on acid secretion in animals. Scand. J. Gastroenterol., 24 (Suppl 166), 12-17.
12. +-ATPase. Biochim. Biophys. Acta, 1148, 223-233.
13. Cederberg G., Ekenved G., Lind T., Olbe L. (1985) : Acid inhibitory characteristics of omeprazole in man. Scand. J. Gastroenterol., 20 (Suppl 108), 105-112.
14. Larsson H., Carlsson E., Junggren U.et al. (1983) : Inhibition of gastric acid secretion by omeprazole in the dog and rat. Gastroenterology, 85, 900-907.
15. Lind T., Cederberg G., Ekenved G., Haglund U., Olbe L. (1983) : Effect of omeprazole - a gastric proton pump inhibitor - on pentagastrin stimulated acid secretion in man. Gut, 24, 270-276.
16. Tateno M., Nakamura N. (1991) : Phase I study of lansoprazole (AG-1749) antiulcer agent - capsule form. Rinsho lyaku, 7, 51-62.
17. Lind T., Cederberg C., Ekenved G., Haglund U., Olbe L. (1983) : Effect of omeprazole - a gastric proton pump inhibitor - on pentagastrin stimulated acid secretion in man. Gut, 24, 270-276.
18. Cederberg C., Lind T., Röhss K., Olbe L. (1992) : Comparison of once-daily intravenous and oral omeprazole on pentagastrin-stimulated acid secretion in duodenal ulcer patients. Digestion, 53, 171-178.
19. Katashima M., Yamamoto K., Sugiura M., Sawada Y., Iga T. (1995) : Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats. Drug Metab. Dispos., 23, 718-723.
20. Simon B., Müller P., Marinis E. et al. (1990) : Effect of repeated oral administration of BY 1023/SK&F 96022 - a new substituted benzimidazole derivative - on pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man. Aliment. Pharmacol. Ther., 4, 373-379.
21. +-ATPase-inhibitor pantoprazole (BY 1023/SK&F 96022) in healthy volunteers. Z. Gastroenterol., 28, 443-447.
22. Anderson T., Andén K., Cederberg C., Lagerström P. O., Lundborg P., Skånberg I. (1990) : Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. Br. J. Clin. Pharmacol., 29, 557-563.
23. Anderson T. (1996) : Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Clin Pharmacokinet., 31, 9-28.
24. Benet L.Z., Zech K. (1994) : Pharmacokinetics - a relevant factor for the choice of a drug? Aliment; Pharmacol. Ther., 8, 25-32.
25. Miwa K., Mitani M., Tsukamoto T. et al. (1990) : Jpn. Pharmacol. Ther., 18, 3413-3435.
26. + ATPase. Annu. Rev. Pharmacol. Toxicol., 35, 277-305.
27. +)ATPase by 2-((2-pyridyl-methyl)-sulphinyl)-benzimidazoles: improved pH selectivity of dialkoxypyridyl-derivatives. Gastroenterol. Int., 1 (Suppl. 1), 1157.
28. Beil W., Staar U., Sewing K-Fr. (1992) : Pantoprazole: a novel H+/K+-ATPase inhibitor with an improved pH stability. Eur. J. Pharmacol., 218, 265-271.
29. +-adenosinetriphosphatase. Biochemistry, 32, 2345-2355.
30. Sachs G., Shin J.M., Besancon M., Prinz C. (1993) : The continuing development of acid pump inhibitors. Aliment. Pharmacol. Ther., 7, 4-12.
31. Satoh H., Inatomi N., Nagaya H. et al. (1989) : Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats. J. Pharmacol. Exp. Ther., 248, 806-815.
32. Kromer W., Postius S., Riedel R. et al. (1990) : BY 1023/SK&F 96022 INN pantoprazole, a novel gastric proton pump inhibitor, potently inhibits acid secretion but lacks relevant cytochrome P450 interactions. J. Pharmacol. Exp. Ther., 254, 129-135.
33. Bliesath H., Simon B., Hartmann M. et al. (1992) : Reduction of pentagastrin stimulated acid output: a suitable method to predict efficacy of an irreversible proton pump inhibitor in peptic ulcer disease. Int. J. Clin. Pharmacol. Ther. Toxicol., 30, 439.